H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on SAGE Therapeutics (NASDAQ:SAGE) on Monday, setting a price target of $76, which is approximately 93.88% above the present share price of $39.2.
Tsao expects SAGE Therapeutics to post earnings per share (EPS) of -$3.25 for the second quarter of 2020.
The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $62.5.
The analysts price targets range from a high of $96 to a low of $35.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $1.96 million and a net profit of -$174.64 million. The company's market cap is $2.04 billion.
According to TipRanks.com, H.C. Wainwright analyst Douglas Tsao is a 5-star analyst with an average return of 11.1% and a 57.2% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.